ClinicalTrials.gg
CompletedNCT06262477Updated Oct 6, 2025Results posted

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

A Phase 1 interventional study of BIIB800 and Actemra in Healthy Volunteer, sponsored by Biogen. Completed at 4 sites in 2 countries. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-06.

Sponsored by Biogen · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

The primary objective of the study is to show equivalence in pharmacokinetics (PK) of BIIB800 and Actemra following SC administration of a single dose to healthy male participants. The secondary objective of the study is to evaluate PK over time, clinical safety, pharmacodynamic (PD) profiles and immunogenicity of BIIB800 and Actemra.

02

Conditions studied

  • Healthy Volunteer
03

In context

Lead sponsor

Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.

Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Have a between 18.5 and 29.9 kilograms per meter square (kg/m\^2), inclusive.
  • Total body weight between 60.0 and 90.0 kg, inclusive.
  • Systolic blood pressure \<135 millimeters of mercury (mmHg) or >85 mmHg at Screening, after being supine for at least 5 minutes.
  • No (as determined by the Investigator) 12-lead (ECG) abnormalities, no cardiac pacemaker.

Key Exclusion Criteria:

  • History or positive test result at Screening for (HIV).
  • History of infection or positive test result at Screening for hepatitis C virus antibody.
  • Current infection (defined as positive for hepatitis B surface antigen [HBsAg] and total hepatitis B core antibody [anti-HBc]).
  • Serious infection (as determined by the Investigator) within the 6 months prior to Screening.
  • History of systemic reaction to the active drug substance, the contained in the formulation, and if appropriate, any diagnostic agents to be administered during the study.
  • History of immunodeficiency or other clinically significant immunological disorders, or disorders.
  • History of clinically significant (in the opinion of the Investigator) atopic allergy (e.g., asthma, urticaria, eczematous dermatitis, allergic rhinitis), hypersensitivity, or allergic reactions.
  • History of angioedema.
  • A positive diagnostic tuberculosis test result within 35 days prior to Day -1, defined as a positive QuantiFERON® test result or 2 successive indeterminate QuantiFERON test results.
  • Any prior exposure to tocilizumab or to any other agent directly acting on IL-6 or on its receptors including products (e.g., siltuximab, sarilumab etc.).
  • Administration of immunoglobulins for anti-tetanus and anti-rabies post-exposure prophylaxis within 3 weeks prior to administration of study drug.
  • Any live or attenuated immunization or vaccination given within 30 days prior to Day -1 or planned to be given during the study period.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    BIIB800

    Participants will receive a single dose of BIIB800 via autoinjector, administered SC in the outer area of the upper arm on Day 1 of the study.

    Drug: BIIB800

  • Experimental
    Actemra

    Participants will receive a single dose of Actemra via autoinjector, administered SC in the outer area of the upper arm on Day 1 of the study.

    Drug: Actemra

Interventions

  • Administered as specified in the treatment arm.

    Also known as: BAT1806

  • Administered as specified in the treatment arm.

    Also known as: Tocilizumab, RoActemra

06

What researchers measure

Primary outcomes

  1. Maximum Observed Serum Concentration (Cmax) of Tocilizumab

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

  2. Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tocilizumab

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

  3. Area Under the Concentration-Time Curve up to the Last Measurable Concentration (AUC0-t) of Tocilizumab

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

Secondary outcomes

  1. Time to Reach Cmax (Tmax) of BIIB800 and Tocilizumab

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

  2. Apparent Total Body Clearance (CL/F) of BIIB800 and Actemra

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

  3. Apparent Terminal Half-Life (t1/2) of BIIB800 and Actemra

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

  4. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious AEs (TESAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant who has received a pharmaceutical product, regardless of causal relationship with the product. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease which is temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE that starts during or after dosing or starts prior to dosing and increases in severity after dosing. An SAE is any untoward medical occurrence that results in death, in the view of the Investigator, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, is a medically important event.

    Time frame: From the first dose of study drug up to the end of the study (up to Day 57)

  5. Area Under the Effect-Time Curve (AUE) of Soluble Interleukin-6-Receptor (sIL-6R)

    sIL-6R levels were determined using a validated immunoassay method based on ProteinSimple Ella.

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

  6. Maximum Observed Effect (Emax) of sIL-6R

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

  7. Time to Emax (tEmax) of sIL-6R

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

  8. AUE of High Sensitivity C-Reactive Protein (hsCRP)

    hsCRP was determined using a particle enhanced immunoturbidometric assay.

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

  9. Minimum Observed Effect (Emin) of hsCRP

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

  10. Time to Emin (tEmin) of hsCRP

    Time frame: Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)

  11. Number of Participants With Positive Tocilizumab Anti-drug Antibodies (ADA) and Neutralizing Antibodies (nAb) Status

    The ADA-positive status was determined as a participant with either a pre-existing ADA-positive status (an ADA-positive sample at baseline \[prior to administration of study treatment\]) or a treatment-induced ADA-positive status (a participant with a negative ADA sample at baseline \[pre-dose\] and at least one ADA-positive sample after the administration of the study treatment. The nAb-positive status was determined in the same manner that of ADA status. ADA and nAb were analyzed in human serum using validated electrochemiluminescence (ECL) assays based on the MesoScale Discovery platform and were measured using validated ECL methods.

    Time frame: Day 1 to Day 57

  12. Geometric Mean Titer of Anti-drug Antibodies (ADA)

    ADA titre was defined as a quasi-quantitative expression of the level of ADA in a sample.

    Time frame: Pre-dose, Days 15, 29, 57

07

Results

Posted Oct 6, 2025

Participant flow

Healthy male participants were enrolled in this study from 02 January 2024 to 04 October 2024 at investigative sites in the US and UK.

Participant flow — Overall Study
MilestoneBIIB800Actemra
Started150150
Completed149148
Not completed12
Withdrew: Withdrawal by subject10
Withdrew: Adverse event01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryMaximum Observed Serum Concentration (Cmax) of Tocilizumab
Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Geometric mean · micrograms per milliter (μg/mL)
Maximum Observed Serum Concentration (Cmax) of Tocilizumab
micrograms per milliter (μg/mL)BIIB800Actemra
Maximum Observed Serum Concentration (Cmax) of Tocilizumab10.5 ± 43.310.0 ± 41.3
Statistical analysis
  • BIIB800 vs Actemra · Ratio of glsm: 1.05 · 90.3% CI 0.974 to 1.13
PrimaryArea Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tocilizumab
Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Geometric mean · hours (h)*μg/ mL
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tocilizumab
hours (h)*μg/ mLBIIB800Actemra
Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Tocilizumab2380 ± 44.92240 ± 41.1
Statistical analysis
  • BIIB800 vs Actemra · Ratio of glsm: 1.07 · 90.3% CI 0.988 to 1.15
PrimaryArea Under the Concentration-Time Curve up to the Last Measurable Concentration (AUC0-t) of Tocilizumab
Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Geometric mean · h*μg/ mL
Area Under the Concentration-Time Curve up to the Last Measurable Concentration (AUC0-t) of Tocilizumab
h*μg/ mLBIIB800Actemra
Area Under the Concentration-Time Curve up to the Last Measurable Concentration (AUC0-t) of Tocilizumab2120 ± 45.92000 ± 44.0
Statistical analysis
  • BIIB800 vs Actemra · Ratio of glsm: 1.06 · 90.3% CI 0.985 to 1.15
SecondaryTime to Reach Cmax (Tmax) of BIIB800 and Tocilizumab
Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Median · hours
Time to Reach Cmax (Tmax) of BIIB800 and Tocilizumab
hoursBIIB800Actemra
Time to Reach Cmax (Tmax) of BIIB800 and Tocilizumab84.0 (12.1 to 241)96.0 (24.0 to 168)
SecondaryApparent Total Body Clearance (CL/F) of BIIB800 and Actemra
Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Geometric mean · Liter per hour (L/h)
Apparent Total Body Clearance (CL/F) of BIIB800 and Actemra
Liter per hour (L/h)BIIB800Actemra
Apparent Total Body Clearance (CL/F) of BIIB800 and Actemra0.0680 ± 44.90.0723 ± 41.1
SecondaryApparent Terminal Half-Life (t1/2) of BIIB800 and Actemra
Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Median · hours
Apparent Terminal Half-Life (t1/2) of BIIB800 and Actemra
hoursBIIB800Actemra
Apparent Terminal Half-Life (t1/2) of BIIB800 and Actemra68.5 (36.3 to 202)68.3 (33.0 to 151)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious AEs (TESAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant who has received a pharmaceutical product, regardless of causal relationship with the product. An AE can therefore be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease which is temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE was defined as an AE that starts during or after dosing or starts prior to dosing and increases in severity after dosing. An SAE is any untoward medical occurrence that results in death, in the view of the Investigator, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, is a medically important event.

Time frame:
From the first dose of study drug up to the end of the study (up to Day 57)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious AEs (TESAEs)
ParticipantsBIIB800Actemra
TEAEs7686
TESAEs20
SecondaryArea Under the Effect-Time Curve (AUE) of Soluble Interleukin-6-Receptor (sIL-6R)

sIL-6R levels were determined using a validated immunoassay method based on ProteinSimple Ella.

Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Mean · hours*nanograms per milliliter (h*ng/mL)
Area Under the Effect-Time Curve (AUE) of Soluble Interleukin-6-Receptor (sIL-6R)
hours*nanograms per milliliter (h*ng/mL)BIIB800Actemra
Area Under the Effect-Time Curve (AUE) of Soluble Interleukin-6-Receptor (sIL-6R)209000 ± 68400202000 ± 58200
SecondaryMaximum Observed Effect (Emax) of sIL-6R
Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Mean · ng/mL
Maximum Observed Effect (Emax) of sIL-6R
ng/mLBIIB800Actemra
Maximum Observed Effect (Emax) of sIL-6R459 ± 99.1452 ± 90.6
SecondaryTime to Emax (tEmax) of sIL-6R
Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Median · hours
Time to Emax (tEmax) of sIL-6R
hoursBIIB800Actemra
Time to Emax (tEmax) of sIL-6R336 (4.00 to 1370)336 (144 to 1350)
SecondaryAUE of High Sensitivity C-Reactive Protein (hsCRP)

hsCRP was determined using a particle enhanced immunoturbidometric assay.

Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Mean · hours*milligrams per liter (h*mg/L)
AUE of High Sensitivity C-Reactive Protein (hsCRP)
hours*milligrams per liter (h*mg/L)BIIB800Actemra
AUE of High Sensitivity C-Reactive Protein (hsCRP)1190 ± 14801780 ± 2570
SecondaryMinimum Observed Effect (Emin) of hsCRP
Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Mean · milligrams per liter (mg/L)
Minimum Observed Effect (Emin) of hsCRP
milligrams per liter (mg/L)BIIB800Actemra
Minimum Observed Effect (Emin) of hsCRP0.133 ± 0.1240.131 ± 0.105
SecondaryTime to Emin (tEmin) of hsCRP
Time frame:
Pre-dose on Day 1 and multiple time points post-dose (up to Day 57)
Reported as:
Median · hours
Time to Emin (tEmin) of hsCRP
hoursBIIB800Actemra
Time to Emin (tEmin) of hsCRP72.0 (0 to 483)96.0 (0 to 338)
SecondaryNumber of Participants With Positive Tocilizumab Anti-drug Antibodies (ADA) and Neutralizing Antibodies (nAb) Status

The ADA-positive status was determined as a participant with either a pre-existing ADA-positive status (an ADA-positive sample at baseline \[prior to administration of study treatment\]) or a treatment-induced ADA-positive status (a participant with a negative ADA sample at baseline \[pre-dose\] and at least one ADA-positive sample after the administration of the study treatment. The nAb-positive status was determined in the same manner that of ADA status. ADA and nAb were analyzed in human serum using validated electrochemiluminescence (ECL) assays based on the MesoScale Discovery platform and were measured using validated ECL methods.

Time frame:
Day 1 to Day 57
Reported as:
Count of participants · Participants
Number of Participants With Positive Tocilizumab Anti-drug Antibodies (ADA) and Neutralizing Antibodies (nAb) Status
ParticipantsBIIB800Actemra
ADA2612
nAb219
SecondaryGeometric Mean Titer of Anti-drug Antibodies (ADA)

ADA titre was defined as a quasi-quantitative expression of the level of ADA in a sample.

Time frame:
Pre-dose, Days 15, 29, 57
Reported as:
Geometric mean · titre
Geometric Mean Titer of Anti-drug Antibodies (ADA)
titreBIIB800Actemra
Day 15—160.0 ± 0.0
Day 29201.6 ± 41.7254.0 ± 94.7
Day 57477.3 ± 96.7452.5 ± 152.4

Adverse events

Collected over From the first dose of study drug up to the end of the study (up to Day 57). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BIIB8000/150 (0%)2/150 (1.3%)75/150 (50%)
Actemra0/150 (0%)0/150 (0%)86/150 (57.3%)
Most frequent serious events
Most frequent serious events
EventBIIB800Actemra
Jaw fractureInjury, poisoning and procedural complications1/1500/150
ParesthesiaNervous system disorders1/1500/150
Most frequent other events
Showing 10 of 125
Most frequent other events
EventBIIB800Actemra
NeutropeniaBlood and lymphatic system disorders3/15025/150
HeadacheNervous system disorders13/15016/150
Oropharyngeal painRespiratory, thoracic and mediastinal disorders8/1507/150
RhinorrhoeaRespiratory, thoracic and mediastinal disorders8/1505/150
FatigueGeneral disorders5/1508/150
Back painMusculoskeletal and connective tissue disorders4/1507/150
White blood cell count decreasedInvestigations1/1507/150
Injection site bruisingGeneral disorders6/1505/150
ArthralgiaMusculoskeletal and connective tissue disorders1/1506/150
CoughRespiratory, thoracic and mediastinal disorders5/1502/150

Baseline characteristics

The all participants analysis set (APAS) included all participants who provided informed consent and had any protocol-led assessment recorded in the study clinical database (i.e., excluded screen failures).

Age, Continuous
Age, Continuous(years)BIIB800ActemraTotal
Mean33.9 ± 9.3434.0 ± 9.9333.9 ± 9.62
Sex: Female, Male
Sex: Female, Male(Participants)BIIB800ActemraTotal
Female000
Male150150300
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BIIB800ActemraTotal
Hispanic or Latino201939
Not Hispanic or Latino130130260
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)BIIB800ActemraTotal
Race — White108108216
Race — Black or African American232548
Race — Asian101121
Race — Multiple8513
Race — American Indian or Alaska Native011
Race — Other101
08

Study locations

4 sites
  • Fortrea Clinical Research Unit Inc.
    Daytona Beach, Florida 32117, United States
  • Fortrea Clinical Research Unit Inc.
    Dallas, Texas 75247, United States
  • Fortrea Clinical Research Unit Inc.
    Madison, Wisconsin 53704, United States
  • Fortrea Clinical Research Unit Inc.
    Leeds, West Yorkshire LS2 9LH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Sep 2024, 8 months.

Results were first posted in Oct 2025, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2024
First posted
Feb 16, 2024
StartActual
Jan 2, 2024
Primary completionActual
Sep 25, 2024
CompletionActual
Oct 4, 2024
Results first posted
Oct 6, 2025
Last update
Oct 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06262477
Lead sponsor
Biogen
Responsible party
Sponsor
First posted
Feb 16, 2024
Start date
Jan 2, 2024
Primary completion
Sep 25, 2024
Completion
Oct 4, 2024
Results posted
Oct 6, 2025
Last update
Oct 6, 2025

Study contacts

Medical Director
study director · Biogen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion